expecting something today., page-27

soon to be our obj's story

Echo Therapeutics (OTCBB: ECTE), in highly anticipated news, has successfully completed a clinical study regarding its Prelude SkinPrep System. The Prelude SkinPrep System is a needle-free platform technology which provides for enhanced skin permeation for the delivery of topical pharmaceuticals. In this case, the clinical study focused on the application of OTC 4% lidocaine cream for faster acting local dermal anesthesia. Without knowing details of the results, we are confident in the success of the clinical study simply by the fact that the Company intends to submit a 510(k) premarket notification to the United States Food and Drug Administration in anticipation of market clearance and product sales.

An abridged version of the book entitled, Prelude SkinPrep System for Dummies, would read something like this. Lidocaine cream is a topical anesthetic used in clinical procedures to control pain on the surface of the skin. Upon application, it can take up to 60 minutes for lidocaine to permeate the skin. Imagine that, you go to the doctor for a simple procedure and you spend the majority of the time waiting for the anesthetic, lidocaine, to take effect. Pretty frustrating right, but not much you can do. Until now. Echo?s SkinPrep System painlessly removes dead skin, thereby allowing the lidocaine to permeate more quickly. In conjunction with Echo Therapeutics? Prelude SkinPrep System, lidocaine is able to penetrate the skin significantly faster. We don?t have access to data from the clinical study, but it could be as quick as ten minutes or less.

So what?s next? First, the submission of a 510(k) premarket notification to the FDA. Second, market clearance by the FDA. Third, FDA clearance would trigger a $750,000 milestone payment from the Company?s partner, Ferndale Pharma Group, Inc. And fourth, revenue opportunities begin. Pretty exciting time for Echo Therapeutics and there is still so much more to talk about.